Specializing In
- Bladder Cancer
- Genitourinary Cancer
Biography
Dr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He also has studied health care utilization and costs for end-of-life care of cancer patients.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers.
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He also has studied health care utilization and costs for end-of-life care of cancer patients.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers.
View Full Biography
Professional Summary
Education & Certifications
- Residency: UCSF Dept of Internal Medicine (2016) CA
- Board Certification: American Board of Internal Medicine, Hematology (2020)
- Board Certification: American Board of Internal Medicine, Medical Oncology (2020)
-
- Medical Education: University of California San Diego School of Medicine (2013) CA
- Board Certification, American Board of Internal Medicine, Oncology
- Board Certification, American Board of Internal Medicine, Hematology
- Board Certification, American Board of Internal Medicine, Internal Medicine
- Fellowship, University of Washington, Seattle, Hematology/Oncology
- M.S., University of Washington School of Public Health, Epidemiology (2020)
- Fellowship: Fred Hutchinson Cancer Research Center (2020) WA
Honors & Awards
- Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology (ASCO) (2019 (ASCO Quality Symposium))
- John Quale Travel Fellowship, Bladder Cancer Advocacy Network (BCAN) (2020)
- Reza Gandjei Resident Humanism Award, University of California, San Francisco (2016)
-
- San Antonio Breast Cancer Symposium Clinical Scholar Award, San Antonio Breast Cancer Symposium (2020)
Administrative Appointments
- Unit Based Medical Director, Stanford Healthcare (2021 - Present)
-
Publications
-
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., … Warner, J. L. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England). -
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C.-Y., … Warner, J. L. (2020). Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discovery. -
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki, A. R., Li, A., Diamantopoulos, L. N., Miller, N. J., Carril-Ajuria, L., Castellano, D., … Grivas, P. (2021). A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology. -
-
Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer.
Desai, A., Khaki, A. R., & Kuderer, N. M. (2020). Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer. JAMA Oncology. -
Loose Regulatory Standards Portend a New Era of Imprecision Oncology.
Khaki, A. R. (2021). Loose Regulatory Standards Portend a New Era of Imprecision Oncology. Cancer Investigation, 1–4. -
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.
Diamantopoulos, L. N., Holt, S. K., Khaki, A. R., Sekar, R. R., Gadzinski, A., Nyame, Y. A., … Wright, J. L. (2020). Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clinical Genitourinary Cancer. -
Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists.
Graham, L. S., Sokolova, A. O., Khaki, A. R., Wu, Q. V., & Davidson, N. E. (2021). Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Investigation, 39(1), 21–24. -
Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State.
Khaki, A. R., Xu, Y., Cheung, W. Y., Li, L., Fedorenko, C., Grivas, P., … Shankaran, V. (2020). Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. JCO Oncology Practice, 16(12), e1543–e1552. -
Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.
Khaki, A. R., Agarwal, N., Pal, S. K., & Grivas, P. (2020). Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. Cancer, 126(20), 4446–50. -
Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board.
Kennedy, L. C., Wong, K. M., Kamat, N. V., Khaki, A. R., Bhatia, S., Thompson, J. A., & Grivas, P. (2020). Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. Targeted Oncology, 15(4), 541–48. -
Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature.
Diamantopoulos, L. N., Khaki, A. R., Sonpavde, G. P., Venur, V. A., Yu, E. Y., Wright, J. L., & Grivas, P. (2020). Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. Clinical Genitourinary Cancer, 18(3), e266–e276. -
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Miller, N. J., Khaki, A. R., Diamantopoulos, L. N., Bilen, M. A., Santos, V., Agarwal, N., … Grivas, P. (2020). Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. The Journal of Urology, 204(1), 63–70. -
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Khaki, A. R., Li, A., Diamantopoulos, L. N., Bilen, M. A., Santos, V., Esther, J., … Grivas, P. (2020). Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 126(6), 1208–16. -
Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.
Khaki, A. R., Gadi, V. K., & Prasad, V. (2019). Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. Journal of the National Comprehensive Cancer Network : JNCCN, 17(12), 1456–58. -
Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes
Diamantopoulos, L. N., Khaki, A. R., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C., … Wright, J. L. (2020). Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. BLADDER CANCER, 6(1), 71–81. -
Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis
Di Tanna, G. L., Khaki, A. R., Theron, G., McCarthy, K., Cox, H., Mupfumi, L., … Bandason, T. (2019). Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. LANCET GLOBAL HEALTH, 7(2), E191–E199. -
Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis
Rifkin, D. E., Khaki, A. R., Jenny, N. S., McClelland, R. L., Budoff, M., Watson, K., … Allison, M. A. (2014). Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis. AMERICAN JOURNAL OF HYPERTENSION, 27(6), 801–10. -
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.
Diamantopoulos, L. N., Sekar, R. R., Holt, S. K., Khaki, A. R., Miller, N. J., Gadzinski, A., … Wright, J. L. (2021). Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urologic Oncology. -
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
Esagian, S. M., Khaki, A. R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., … Grivas, P. (2021). Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International. -
Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.
Sekar, R. R., Diamantopoulos, L. N., Khaki, A. R., Vakar-Lopez, F., Tretiakova, M. S., Psutka, S. P., … Wright, J. L. (2020). Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.
Diamantopoulos, L. N., Sekar, R. R., Khaki, A. R., Miller, N., Gadzinski, A. J., Psutka, S. P., … Wright, J. L. (2020). Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes.
Nelson, A. A., Cronk, R., Szabo, A., Lemke, E., Giever, T. A., Burfeind, J. D., … Hoimes, C. J. (2020). Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Perioperative Immunotherapy in Muscle-invasive Bladder Cancer.
Tripathi, A., Khaki, A. R., & Grivas, P. (2021). Perioperative Immunotherapy in Muscle-invasive Bladder Cancer. European Urology Oncology. -
Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis.
Wagner, M. J., Pollack, S. M., Cranmer, L. D., Thompson, M. J., Maxwell, S., Wright, S., … Loggers, E. T. (2021). Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. Cancer Investigation, 1–11. -
Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study
Khaki, A. R., Shah, D. P., Lustberg, M. B., Accordino, M. K., Stover, D. G., Nagaraj, G., … Vinayak, S. (2021). Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study. CANCER RESEARCH, 81(4). -
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.
Khaki, A. R., Shan, Y., Nelson, R. E., Kaul, S., Gore, J. L., Grivas, P., & Williams, S. B. (2021). Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. Urologic Oncology. -
Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
Makrakis, D., Diamantopoulos, L. N., Koshkin, V. S., Alva, A. S., Bilen, M. A., Stewart, T. F., … Khaki, A. R. (2021). Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).
Khaki, A. R., Shan, Y., Nelson, R., Kaul, S., Gore, J. L., Grivas, P., & Williams, S. B. (2021). Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
Makrakis, D., Castellano, D., de Kouchkov, I., Park, J. J., Bilen, M. A., Agarwal, N., … Khaki, A. R. (2021). Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20.
Lythgoe, M., Julve, M., Krell, J., Savage, P., Grivas, P., & Khaki, A. R. (2021). Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20. JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).
Tucker, M. D., Schmidt, A. L., Hsu, C.-Y., Shyr, Y., Armstrong, A. J., Bakouny, Z., … McKay, R. R. (2021). Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.
Esagian, S. M., Khaki, A. R., Carril-Ajuria, L., Park, J. J., Bilen, M. A., Stewart, T. F., … Petros, G. (2021). Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes. JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.
Koshkin, V. S., Sun Yilun, Freeman, D., Osterman, C. K., Su, C., Natesan, D., … Alva, A. S. (2021). Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study. JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.
Michailidou, D., Khaki, A. R., Morelli, M. P., Diamantopoulos, L., Singh, N., & Grivas, P. (2021). Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Scientific Reports, 11(1), 9029. -
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma
Nelson, A. A., Cronk, R. J., Lemke, E. A., Szabo, A., Khaki, A. R., Diamantopoulos, L. N., … Hoimes, C. J. (2021). Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma. BLADDER CANCER, 7(1), 33–42. -
Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras.
Khaki, A. R., Chennupati, S., Fedorenko, C., Li, L., Sun, Q., Grivas, P., … Shankaran, V. (2021). Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. JCO Oncology Practice, OP2001050. -
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.
Diamantopoulos, L. N., Khaki, A. R., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C., … Wright, J. L. (2020). Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. Bladder Cancer (Amsterdam, Netherlands), 6(1), 71–81. -
Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center.
Yoke, L. H., Lee, J. M., Krantz, E. M., Morris, J., Marquis, S., Bhattacharyya, P., … Liu, C. (2021). Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center. Open Forum Infectious Diseases, 8(6), ofab193. -
Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population.
Khaki, A. R., Glisch, C., & Petrillo, L. A. (2021). Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population. JCO Oncology Practice, OP2100397. -
Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review.
Sharp, J., Khaki, A. R., & Prasad, V. (2021). Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review. JAMA Network Open, 4(9), e2124728. -
Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer.
Makrakis, D., Talukder, R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., … Khaki, A. R. (2021). Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer. BJU International. -
Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020
Chiang, R. S., Glover, M., Hui, G., Desai, A., Wakelee, H. A., Lythgoe, M., & Khaki, A. R. (2021). Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of treatment type with patient-reported quality of life in cancer distress screening
Roy, M., Rosenthal, S., Shah, M. P., Khaki, A. R., Bozkurt, S., Seto, T., … Ramchandran, K. (2021). Association of treatment type with patient-reported quality of life in cancer distress screening. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room.
Nath, S. S., Yadav, N. U., Derkach, A., Perez-Johnston, R., Tachiki, L., Maguire, K., … Groeger, J. (2021). Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. Cancer Investigation, 1–9. -
Disparity of Race Reporting in FDA Drug Approvals for Urinary System Cancers from 2006 to 2021.
Glover, M., Hui, G., Chiang, R., Savage, P., Krell, J., Julve, M., … Khaki, A. R. (2021). Disparity of Race Reporting in FDA Drug Approvals for Urinary System Cancers from 2006 to 2021. BJU International. -
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt, A. L., Tucker, M. D., Bakouny, Z., Labaki, C., Hsu, C.-Y., Shyr, Y., … McKay, R. R. (2021). Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 4(11), e2134330. -
Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.
Loggers, E. T., Wulff-Burchfield, E. M., Subbiah, I. M., Khaki, A. R., Egan, P., Farmakiotis, D., … Warner, J. L. (2021). Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.
Wagner, M. J., Ingham, M., Painter, C., Chugh, R., Trent, J. C., Subbiah, V., … Davis, E. J. (2021). Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.
Lythgoe, M., Krell, J., Warner, J. L., Desai, A., & Khaki, A. R. (2021). Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Patients' perception of meaning of life and needed support before and after cancer treatment initiation
Roy, M., Rosenthal, S., Shah, M., Khaki, A., Hernandez-Boussard, T., & Ramchandran, K. (2021). Patients' perception of meaning of life and needed support before and after cancer treatment initiation. QUALITY OF LIFE RESEARCH. SPRINGER. -
Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).
Stewart, T. F., Kotha, N. V., Dzimitrowicz, H. E., Makrakis, D., Khaki, A. R., Simon, N. I., … McKay, R. R. (2021). Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.
Makrakis, D., Talukder, R., Carril, L., de Kouchkovsky, I., Park, J. J., Bilen, M. A., … Khaki, A. R. (2021). Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin, V. S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., … Alva, A. S. (2021). Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. -
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Talukder, R., Makrakis, D., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., … Khaki, A. R. (1800). Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer. -
Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
Parikh, D. A., Khaki, A. R., & Williams, S. B. (2022). Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study. European Urology. -
Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
Golla, V., Shan, Y., Farran, E. J., Stewart, C. A., Vu, K., Yu, A., … Williams, S. B. (2022). Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urologic Oncology. -
Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.
Elkrief, A., Hennessy, C., Kuderer, N. M., Rubinstein, S. M., Wulff-Burchfield, E., Rosovsky, R. P., … Wildes, T. M. (2022). Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. The Lancet. Healthy Longevity. -
Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., … Khaki, A. R. (2022). Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
Golla, V., Shan, Y., Farran, E. J., Vu, K., Stewart, C. A., Khaki, A. R., … Williams, S. B. (2022). Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).
Makrakis, D., Talukder, R., Dawsey, S., Carril, L., Stewart, T. F., Morales-Barrera, R., … Khaki, A. R. (2022). Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe, M. P., Desai, A., Gyawali, B., Savage, P., Krell, J., Warner, J. L., & Khaki, A. R. (2022). Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. JAMA Network Open, 5(6), e2216183. -
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., … Khaki, A. R. (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. -
Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study
Parikh, D. A., Kaki, A. R., & Williams, S. B. (2022). Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study. EUROPEAN UROLOGY, 81(4), 429–430. -
Considerations in the reliability and fairness audits of predictive models for advance care planning
Lu, J., Sattler, A., Wang, S., Khaki, A. R., Callahan, A., Fleming, S., … Shah, N. (2022). Considerations in the reliability and fairness audits of predictive models for advance care planning. Frontiers in Digital Health. -
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
Wagner, M. J., Hennessy, C., Beeghly, A., French, B., Shah, D. P., Croessmann, S., … Davis, E. J. (2022). Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers, 14(17). -
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder, R., Makrakis, D., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., … Khaki, A. R. (2022). Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. -
Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020.
Chiang, R. S., Desai, A., Glover, M. J., Hui, G., Ramchandran, K. J., Wakelee, H., … Khaki, A. R. (2022). Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020. Cancer Investigation, 1–6. -
Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.
Chiang, R. S., Glover, M. J., Khaki, A. R., & Srinivas, S. (2022). Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab. OncoTargets and Therapy, 15, 1259–1269. -
Use of systemic cancer treatments based on a validated survival prediction model in metastatic cancer.
Roy, M., Gensheimer, M. F., Chang, D. T., Singhal, S., & Khaki, A. R. (2022). Use of systemic cancer treatments based on a validated survival prediction model in metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Reducing inpatient mortality in patients with cancer through multidisciplinary review and targeted interventions.
Shah, M. P., Garrigues, S. K., Khaki, A. R., Hansen, J., Divi, V., & Blayney, D. W. (2022). Reducing inpatient mortality in patients with cancer through multidisciplinary review and targeted interventions. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Patient-reported distress at a cancer center during the COVID-19 pandemic.
Shah, M. P., Rosenthal, S., Roy, M., Khaki, A. R., Hernandez-Boussard, T., & Ramchandran, K. (2022). Patient-reported distress at a cancer center during the COVID-19 pandemic. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Using real-world data to assess variations in cost and healthcare utilization for patients diagnosed with bladder cancer.
Boehmer, L., Khaki, A. R., Carthon, B. C., Davis, N. B., Washington, S. L., Goltz, H. H., … Mangir, C. (2022). Using real-world data to assess variations in cost and healthcare utilization for patients diagnosed with bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128. -
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Makrakis, D., Bakaloudi, D. R., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Jindal, T., … Koshkin, V. S. (2022). Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. -
Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?
Khaki, A. R., Lythgoe, M. P., & Prasad, V. (2023). Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint? Journal of Cancer Policy, 35, 100402. -
Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature
Hui, G., Khaki, A. R., & Grivas, P. (2022). Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature. JOURNAL OF CANCER METASTASIS AND TREATMENT, 8. -
Geriatric assessment in the older adult with genitourinary cancer: A narrative review.
Singhal, S., Marwell, J. G., & Khaki, A. R. (2023). Geriatric assessment in the older adult with genitourinary cancer: A narrative review. Frontiers in Oncology, 13, 1124309. -
Immune related liver toxicity and potential risk factors: A case-control study
Storm, E. M., Makraki, D., Lin, G. I., Kennedy, L. C., Shah, E. E., Phipps, A. I., … Khaki, A. R. (2022). Immune related liver toxicity and potential risk factors: A case-control study. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
Sekar, R. R., Diamantopoulos, L. N., Bakaloudi, D. R., Khaki, A. R., Grivas, P., Winters, B. R., … Wright, J. L. (2023). Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy. Clinical Genitourinary Cancer. -
Patient-reported distress at a cancer center during the COVID-19 pandemic.
Shah, M. P., Rosenthal, S. W., Roy, M., Khaki, A. R., Hernandez-Boussard, T., & Ramchandran, K. (2023). Patient-reported distress at a cancer center during the COVID-19 pandemic. Scientific Reports, 13(1), 9581. -
Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case-Control Study.
Storm, E. M., Makrakis, D., Lin, G. I., Talukder, R., Bakaloudi, D. R., Shah, E. E., … Khaki, A. R. (2023). Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case-Control Study. Targeted Oncology. -
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Bakaloudi, D. R., Talukder, R., Lin, G. I., Makrakis, D., Diamantopoulos, L. N., Tripathi, N., … Grivas, P. (2023). Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. Clinical Genitourinary Cancer. -
Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma.
Bojanini, L., Gupta, N., & Khaki, A. R. (2023). Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma. The Oncologist. -
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
El Zarif, T., Nassar, A. H., Pond, G. R., Zhuang, T. Z., Master, V., Nazha, B., … Sonpavde, G. P. (2023). Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. Journal of the National Cancer Institute. -
Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C.-S., Shah, S., … Khaki, A. R. (2023). Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
Talukder, R., Bakaloudi, D. R., Lin, G. I., Enright, T., Leary, J. B., Makrakis, D., … Grivas, P. (2023). Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Assessment of price variation in colorectal cancer screening procedures at US hospitals.
Paranjpe, I., Sharma, P., Wei, C., Puram, V., Kamat, S., & Khaki, A. R. (2023). Assessment of price variation in colorectal cancer screening procedures at US hospitals. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study.
Nagaraj, G., Vinayak, S., Khaki, A. R., Sun, T., Kuderer, N. M., Aboulafia, D. M., … Shah, D. P. (2023). Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study. ELife, 12. -
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Nagaraj, G., Vinayak, S., Khaki, A. R., Sun, T., Kuderer, N. M., Aboulafia, D. M., … Shah, D. P. (2023). Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. MedRxiv : the Preprint Server for Health Sciences. -
The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
Hensley, P. J., Choudhury, A., Khaki, A. R., Grivas, P., & Kamat, A. M. (2023). The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal. European Urology. -
Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.
Khaki, A. R., Fan, A. C., Shah, S., Parikh, D. A., Chien, J., Moore, K., … Srinivas, S. (2023). Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC).
Talukder, R., Bakaloudi, D. R., Makrakis, D., Tripathi, N., Agarwal, N., Jindal, T., … Khaki, A. R. (2023). Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC): "Real world" experience.
Bakaloudi, D. R., Talukder, R., Makrakis, D., Agarwal, N., Tripathi, N., Bamias, A., … Grivas, P. (2023). Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC): "Real world" experience. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, T., Kilari, D., Alhalabi, O., Nizam, A., Khaki, A. R., Basu, A., … Koshkin, V. S. (2023). Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database.
Shen, J., Wang, L., Khaki, A. R., Jimenez, R. E., Mauer, E., Stoppler, M. C., … Kohli, M. (2023). Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., … Iagaru, A. (2024). Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. -
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.
Nelson, A. A., Cronk, R. J., Lemke, E. A., Szabo, A., Khaki, A. R., Diamantopoulos, L. N., … Hoimes, C. J. (2021). Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma. Bladder Cancer (Amsterdam, Netherlands), 7(1), 33–42. -
An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study.
Tkacz, J., Ireland, A., Agatep, B., Ellis, L., Balaji, H., & Khaki, A. R. (2024). An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study. Journal of Medical Economics, 1–14. -
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.
Rasco, D. W., Razak, A. R. A., Khaki, A. R., Spira, A. I., Hwang, C.-C., Diep, A. N., … Glatt, D. M. (2024). Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort
Khaki, A. R., Razak, A. R. A., Laurie, S. A., Hwang, C.-C., Diep, A. N., Schmidt, M., … Krystal, J. (2024). Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023
Warner, J. L., Bakow, B. R., Brown, A. J., Choe, J. H., Fan, E., Ganta, T., … Rubinstein, S. (2024). Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH)
Rafailia Bakaloudi, D., Makrakis, D., Talukder, R., Nikolaos Diamantopoulos, L., Jindal, T., Nguyen, C. B., … Grivas, P. (2024). Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.
Gage, S., Eteshola, E., Hadfield, M. J., Hamze, D., Khaki, A. R., Mishra, S., … Warner, J. L. (2024). Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
Bakaloudi, D. R., Talukder, R., Makrakis, D., Diamantopoulos, L., Enright, T., Leary, J. B., … Khaki, A. R. (2024). Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clinical Genitourinary Cancer, 22(6), 102198. -
Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC).
Bolan, P., Hui, G., Low, Y., Gombar, S., Fan, A. C., Parikh, D. A., … Khaki, A. R. (2024). Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)
Bergstrom, C. P., Song, H., Ruiz, S. M., Chien, J., Moore, K., Parikh, D. A., … Khaki, A. R. (2024). Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Total and anatomically contextualized quantitative <SUP>18</SUP>F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.
Song, H., Anand, A., Sjostrand, K., Ferri, V., Duan, H., Shah, J., … Iagaru, A. (2024). Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of <SUP>177</SUP>Lu-PSMA-617 treatment.
Leonio, M. I., Ferri, V., Duan, H., Shah, J., Moradi, F., Mari Aparici, C., … Iagaru, A. (2024). Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of 177Lu-PSMA-617 treatment. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Comparative cost-effectiveness of trimodal therapy and radical cystectomy for management of muscle-invasive bladder cancer.
Joyce, D. D., Wymer, K., Boorjian, S. A., Gore, J. L., Khaki, A. R., Raldow, A. C., … Sharma, V. (2024). Comparative cost-effectiveness of trimodal therapy and radical cystectomy for management of muscle-invasive bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.
Jindy, T., Jiang, C. Y., Alhalabi, O., Nguyen, C. B., Nizam, A., Basu, A., … Koshkin, V. S. (2024). Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)
Bakaloudi, D. R., Talukder, R., Makrakis, D., Diamantopoulos, L. N., Patgunarajah, U., Thomas, V. M., … Khaki, A. R. (2024). Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Describing the genomic landscape of bladder cancer histologic subtypes
Talukder, R., Berg, R., Huang, M., Nepomucino, V. M., Stoppler, M. C., Makrakis, D., … Grivas, P. (2024). Describing the genomic landscape of bladder cancer histologic subtypes. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
Khanna, S., Sarwar, N., Caldwell, R., Krell, J., Benjamin, D. J., Hadfield, M. J., … Lythgoe, M. (2024). Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Jindal, T., Jiang, C., Alhalabi, O., Nizam, A., Nguyen, C., Talukder, R., … Koshkin, V. S. (2024). Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. European Urology Oncology. -
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Talukder, R., Bakaloudi, D. R., Makrakis, D., Diamantopoulos, L. N., Enright, T., Leary, J. B., … Grivas, P. (2024). Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 23(1), 102284.
-
Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
- HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
- A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
- Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Practice Locations
Urologic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Urologic Cancer Program in Palo Alto
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(154 reviews)
Just keep on doing what you are doing. This was a pleasant video visit. Dr. Khaki and his staff made it so.
I liked his energy and he didn’t seem rushed!
This was my first meeting with Dr. Khaki.
Key impressions:
- I did not feel rushed
- Both doctors were patient with my questions
- Bedside manner was reassuring and refreshing
Dr, khaki is kind, he listens and very professional. He cares about his patients.
Always very professional, knowledgable, and caring.
Dr. Khaki is renowned in the industry and by his patients.
Awesome doctor
he's excellent.
Its always a pleasure to see and talk with Dr Khaki via a video visit. He is very informative, answers all my questions and is very attentive and explains everything about my condition and the treatments that are available along with the expected side effects. He is in constant communication with my local oncologist Dr Cao(in Santa Rosa). I highly respect him as a doctor and have complete trust in his judgement regarding my care
Staff were excellent
Great doctor and very knowledgeable about my medical issues. Very kind and answered all my concerns and questions. He is an asset to Stanford Medical.
I like Dr Kahki’s explanations of whatever we’re talking about. Could be medicine could be the condition could be possible issues. Everything I’ve talked to him about I’ve been clearly explained.
Friendly, positive; engaging, and approachable
Dr. Khaki has always been knowledgable, helpful and patient.
he's great. I'm grateful for his care.
Dr. Khaki is very knowledgeable. He listens, explains and answers all questions. Very pleased to have Dr. Khaki on board for my cancer care.
He's wonderful, I love being his patient.
I like him. He seems to be very thorough and informative.
Dr. Khaki is excellent. Video, or on-line content is very challenging to the provider (Doctor). Unlike a typical University where content is constant, in this type setting content changes with the patient. As previously stated, Dr. Khaki is excellent.
Well done
Liked that he was open to alternative care in place of pushing chemo on me.
Very good presence, open to questions.
Dr. Khaki did his part of the presentation well and we had no technical problems. His support staff were excellent as well.
Dr Khaki is an excellent doctor easy to understand and very patient with me. Listens to me very patient.
Kind, great doctor!
Dr Khaki is an excellent profesional and inspires confidence. He does listen the patient.
He is great and answers all my questions.
Thank you Dr Khaki. I very much appreciate you and your team for your excellent care and compassion.
Very nice person, listened. Went above and beyond to call a meso doc and follow up with us by phone.
He was very thorough and summarized the questions and the process for the upcoming steps very well. As a result, I feel like I have a clear understanding of what's next and what to expect.
I love Dr Ali Khaki very much. I think he needs more babies!!!
He is a Great Doctor. Listens very intently.
Thanks
Gives very thorough and easily understandable information
Dr. Khaki is a great doctor. He is knowledgeable, caring, knows what he is doing, explains things well. He is the best doctor I've ever seen.
Very good. Knowledgeable and well prepared when he starts the visit. He knows what medicines and/or clinical trials are available and the rules for the trials. We really like him.
EXCELLENT Dr, had a very good visit. He was good at explaining all things going on
I really like him. I felt very comfortable and at ease talking to him.
Dr Khaki is a class act, so thankful that he is my doctor.
Excellent information and presentation , including Iva , the nurse practitioner
He seemed like a person with whom you could trust with your care. I could not by any means say I know him but his demeanor left me feeling like I could rely on his knowledge to see me through this episode of my life.
Dr. Khaki was very knowledgeable and personable. He listened to all my concerns and is following up on my upcoming treatment.
Dr Khaki is very knowledgeable and kind. He listens and explains information in an easy to understand manner.
Dr Khaki explain well the situations. I have not complains about his treatments.
Thank you and your staff for continued support and excellent medical treatment.
He is exelent doctor
Thanks for caring and being friendly
It was a pleasure to meet Dr Khaki. I instantly felt comfortable and assured that I am receiving the best health care.
He is co ordinating closely with my local oncologist to determine the best treatment for my cancer.
Answered all my questions
Dr Khaki is very knowledgeable, friendly, and listens to the patient. I respect and appreciate his opinion regarding my health condition.
He handled the subject as well as one could have, told me exactly what I needed to know, and answered all my questions. Made me feel that he was invested and cared about my health.
Dr. Khaki is, along with my Stanford team, top drawer. I wish he practiced near my home, However Standford is doable and has been a very positive experience for my cancer treatment.
He’s an excellent MD very thorough.
Professional, courteous, and extremely knowledgeable!
Dr. Khaki was kind and helpful in explaining the condition of my illness. He was very clear on what the next steps for his office and for me. He was very patient in answering my questions.
I appreciated his time and his assistance.
he explain all my question that i had
So far he seems to be "top Notch" and concerned with my case
He was very attentive and answered all of my questions. I thought it was an excellent appointment.
I have a good rapport with Dr. Khaki and he has sensible answers for all my questions.
Explains things beautifully, is through, LISTENS, is sensitive to issues that are important to me.
I give him an '"A" in terms of human interface,----
I consider myself qualified in that I spent almost a dozen years as a standardized patient at Stanford, UCSF qnd others,
More like Dr.Khaki say I,
Such an awesome team.
I have good visits with Dr. Khaki.
Excellent Doctor. Knowledgeable and continues to put me at ease while I deal with my current medical condition.
DR KHAKI IS A VERY KNOWLEDGEABLE AND WELL TRAINED INDIVIDUAL I FEEL QUITE COMFORTABLE WITH HIM AT THE "WHEEL".
I was very impressed with meeting Dr Khaki, he was very informative and answered all y questions and offered suggestions about continuing my treatment and will confer with my local oncologist Dr Cao and my cardiologist Dr Dahr as well. It was a pleasure talking to him today and will see him again in a month to assess my treatments.
Concerned and friendly with patients
Always appreciate Dr. Khaki’s medical knowledge and communication skills during the video appointment. He is always able to share important information and treatment plans that help to relieve any concerns I might have. Excellent Doctor and Team !!
Dr. Khaki is proficient with on line consultation and as good as face to face without 250 miles of commute.
Dr. Khaki is an excellent Oncologist, we’re very happy with him and his plan for treatment.
Obviously intelligent.
Listens carefully to my concerns.
Answers my long list of questions patiently and understandable
Obviously concerned with the patients healthy outcome
He was very pleasant, concerned, and knowledgeable. I highly recommend him.
Dr Khaki went over test results with me and was very thorough in explaining things and letting me know what my next steps are. He listened to my concerns.
Dr. Khaki is an asset to Stanford Medicine and I am fortunate to have him on my team. He is one of the best physicians I have ever had.
Ali is very pleasant communicator, thorough going over all my questions and issues found in my recent records.
Extremely professional, courteous, and knowledgeable! Most of all I was able to understand what Dr. Khaki was telling me.
Dr Khaki is excellent! He is supportive, caring, reassuring, and helpful in his assessments. I am thankful to have him as part of my medical team.
Communicates well and clear. Answered all my questions.
Excellent dr
Dr Khaki is very personable and I felt confident he was up to dat eon my case and had the correct specialties to help me.
Great first visit.
Very professional and on time
Very professional and cares about your well being.
Extremely pleased with commutation!
Excellent Doctor. Looking forward to working with him on my treatment plan.
Excellent oncologist
I like talking to Dr. Very much. It’s almost like talking to an old friend.
Excellent Doctor !! Very caring and excellent communication skills. Listened to my details of all of the events that led up to my current health status.
Professional analysis and advise
Dr. Ali Khaki is an excellent physician.
He and the Intern were very patient friendly. He took his time reviewing my history.
Extremely helpful with ideas for my cancer treatment. I feed very comfortably with him as my doctor.
Excellent Visit.
Dr. Khaki is a gentle and knowledgeable doctor. He has command of his area of specialization. He relates positively with his patients
Excellent customer service and explained very thoroughly.
Excellent doctor. Very caring.
I had an excellent experience with him. He is kind and understanding person that is a huge asset to Stanford Medical. He understood my feeling about the situation and made everything work to my satisfaction. He is a compassionate human being and a model for others.
This was my first visit with Dr. Kakai. Although it was by phone, I felt that my situation was gone over thoroughly and results were communicated clearly. I appreciated the careful review of my records and scans and his obtaining additional review of scans by radiology there at Stanford to confirm his findings. I also appreciated his prompt response to my post visit questions.
He is knowledgeable and open in his communication. I have confidence in his collaboration with my oncologist (Dr. Li) at Sutter Gould.
Dr Khaki was very professional and caring. Very pleased with this visit.
Dr. Khaki listens well, and he is always spot-on with appropriate replies and recommendations.
Very good office visit
Very helpful and considerate
Very professional, and friendly. I would recommend to anyone.
Dr. Khaki is an excellent care provider. He answers all questions and fully explains any and all recommended treatment procedures. I am extremely thankful to have him overseeing my health needs.
Dr Khaki was clear, concise and to the point, all with a good bedside manner.
Dr Khaki is very knowledgable and patient. His response is also quick through message system. Our experience overall with him is great.
He answered all of my questions. He's very warm and caring. His assistant was very nice and informative as well.
Very professional yet very friendly.
Excellent communicator
he was very helpful .
Nice guy. Very knowledgeable and sensible.
He was pleasant, thoughtful and thorough.
I feel very well taken care of by Dr. Khaki and his team.
I’m very satisfied!
He is super and a wonderful asset for Stanford to have.
Very understanding and explanation very clear!
Great Doctor
He was friendly and seemed to be an expert in his field.
Pleasant to communicate with and offers suggestions for further treatment. Very professional.
He is an excellent doctor and a person to talk to and consult with.
This was my first contact with Dr. Ali Khaki. He was very professional, confident, friendly and helpful. He did listen what I had to say and gave a clear picture of what is expected for the first steps of my treatment.
I like him because he takes an interest in me an feels more like a friend.
Very personable
On top of his game!
Dr. Khaki is very clear about expressing, and advising what we need to know, I feel confident about what in his "hands".
Dr Khaki was very cordial and knowledgeable! I felt very comfortable and at ease with Dr Khaki.
Excellent doctor who seems to sincerely care about my health issues
He really understood my situation I appreciated it very much. He explained my options and I was able to ask questions and comments, "my doctor became my friend" and the visit was very informative!!
Dr khaki is patient, charming, good sense of humor, clear in his explanations. A pleasure to have met him.
He either answered my questions clearly or gave me clear information before I even asked. He was also reassuring and easy to talk to.
It was our first meeting after my diagnosis and I was very pleased with Dr. Khaki. He communicated all information in a thorough way and treated me as an intelligent and "real" person and not just a case.
Encouraging discussions
We appreciated that he was a very good listener to our concerns.
Thank you.
very good meeting. felt very comfortable with him.
Dr Khaki is great. He listens and puts me at ease right away. He always asks if I want to tell him about anything I'm feeling or any concerns I have. I'm extremely happy with the care he is providing me.
knows how to treat people and inspires you trust good person and good doctor
Very well spoken and personable, easy to speak with.
I enjoy my appointments with Dr. Khaki. He is very informative & answers all my questions thoroughly. Dr. Khaki also has a very pleasant & positive demeanor
He is a professional and very very good doctor God blessed,thank you for everything, Merry Christmas
Dr. Khaki was professional and reassuring. I am sure I will be in good hands getting care from him and the healthcare team.
He was great and was able to suggest possibilities I hadn't thought of.
The Doctor was very much informed, made me feel relax and gave a warm but concise feel about the treatment. He’s obviously has a great deal of knowledge and has the ability to get bad news across in a good manner.
Thanks
Pleasant. Clear.
OK Pleasant and informative
Dr. Khaki is thorough. He addressed my concerns in a way I understood.
He was very supportive and very thorough to my questions.
I am very pleased with Dr. Khaki.
He is a person who inspires trust and explains the procedure step by step without knowing him I can say that he is an excellent person
Very informative
He is a very good doctor
He was knowledgeable about the topic he was discussing and was pleasant to talk to.
Excellent video conference; very clear & succinct with all my questions with limited initial contact.
Dr. Khaki was excellent in every way.
Dr Khaki was very positive & took the time to answer whatever questions I had. He was very thorough & l appreciated his pleasant demeanor
We really found Ali Khaki to be personable, and felt comfortable during the visit. I would recommend him to others. He put our minds at ease, taking some of the unknown out of the next step in the journey regarding the chemo therapy treatment.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records